Harrow Health Target of Unusually Large Options Trading (NASDAQ:HROW)

Share on StockTwits

Harrow Health (NASDAQ:HROW) saw some unusual options trading activity on Wednesday. Traders bought 750 call options on the company. This represents an increase of 874% compared to the typical volume of 77 call options.

NASDAQ:HROW opened at $5.61 on Thursday. The company has a fifty day moving average of $5.22 and a 200 day moving average of $6.22. Harrow Health has a 52 week low of $4.10 and a 52 week high of $8.99. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $142.48 million, a P/E ratio of 9.20 and a beta of 0.09.

Harrow Health (NASDAQ:HROW) last issued its quarterly earnings data on Wednesday, November 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.27). The company had revenue of $12.76 million for the quarter, compared to analysts’ expectations of $13.31 million. Harrow Health had a net margin of 31.32% and a return on equity of 25.96%. As a group, analysts anticipate that Harrow Health will post -0.08 EPS for the current year.

In related news, Director Robert J. Kammer sold 6,500 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $5.25, for a total transaction of $34,125.00. Insiders have sold a total of 19,500 shares of company stock valued at $101,855 over the last quarter. 12.43% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its position in shares of Harrow Health by 18.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,146,506 shares of the company’s stock worth $9,975,000 after buying an additional 178,700 shares during the period. Vanguard Group Inc. grew its holdings in Harrow Health by 0.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,118,280 shares of the company’s stock valued at $9,729,000 after buying an additional 9,112 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Harrow Health by 40.8% in the 2nd quarter. Acadian Asset Management LLC now owns 560,597 shares of the company’s stock valued at $4,878,000 after buying an additional 162,459 shares in the last quarter. BlackRock Inc. grew its holdings in Harrow Health by 273.3% in the 2nd quarter. BlackRock Inc. now owns 430,524 shares of the company’s stock valued at $3,745,000 after buying an additional 315,209 shares in the last quarter. Finally, Cadence Capital Management LLC purchased a new stake in Harrow Health in the 2nd quarter valued at $2,483,000. 36.29% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently commented on HROW. ValuEngine upgraded shares of Harrow Health from a “strong sell” rating to a “sell” rating in a report on Thursday, November 14th. Zacks Investment Research lowered shares of Harrow Health from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Finally, Lake Street Capital set a $15.00 price target on shares of Harrow Health and gave the company a “buy” rating in a report on Friday, August 16th. Two equities research analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $10.83.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Read More: Understanding the two types of arbitrage

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Berry Petroleum  Given “Hold” Rating at Wells Fargo & Co
Berry Petroleum Given “Hold” Rating at Wells Fargo & Co
John Hancock Hedged Equity and Income Declares Quarterly Dividend of $0.38
John Hancock Hedged Equity and Income Declares Quarterly Dividend of $0.38
Pimco Corporate & Income Strategy Fund  Announces Monthly Dividend of $0.11
Pimco Corporate & Income Strategy Fund Announces Monthly Dividend of $0.11
Cronos Group Inc  Given Consensus Rating of “Hold” by Brokerages
Cronos Group Inc Given Consensus Rating of “Hold” by Brokerages
Bicycle Therapeutics Limited  Given Average Recommendation of “Buy” by Analysts
Bicycle Therapeutics Limited Given Average Recommendation of “Buy” by Analysts
The Currency Analytics  Achieves Market Capitalization of $46,977.00
The Currency Analytics Achieves Market Capitalization of $46,977.00


© 2006-2019 Ticker Report